# PSMA expression by PET (PSMA-positive)

Source: https://onco.cc/biomarkers/psma-pet-expression/  
OnCo record `psma-pet-expression` (Biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PSMA-positive means prostate cancer deposits light up on a PSMA PET scan more than the liver does. It is the entry ticket for lutetium-177 PSMA therapy and the basis of the imaging that now stages most advanced prostate cancer.

## Summary

Gallium-68 gozetotide (Locametz, Illuccix), piflufolastat F-18 (Pylarify) and flotufolastat F-18 (Posluma) image PSMA. The Pluvicto label requires selection with Locametz or another approved PSMA PET product based on PSMA expression in tumours; the VISION and PSMAfore trials defined positivity as at least one metastatic lesion with uptake greater than liver parenchyma and no PSMA-negative lesions above size limits (short axis 1 cm in soft tissue, 2.5 cm in nodes, or any measurable bone lesion with soft tissue component), and the label's clinical studies section repeats this. Pluvicto is now labelled for both PSMA-positive metastatic castration-resistant disease after an ARPI and, since 2026, PSMA-positive metastatic androgen pathway modulation-naive or -sensitive disease with an ARPI.

## Fields

- Kind: Biomarker
- Last checked: 2026-09-23
- Also known as: PSMA PET positive; PSMA-positive; PSMA expression; PSMA PET; Ga-68 PSMA-11 uptake; piflufolastat PET; PSMA-avid; PSMA uptake greater than liver
- Tags: biomarker; pet

## Sources

- PLUVICTO prescribing information (DailyMed): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14908037-2892-4d98-a053-253ce35afb1a

## Connected records

- biomarkers: [AR-V7 splice variant](https://onco.cc/biomarkers/ar-v7-splice-variant/), [Somatostatin receptor expression by PET (SSTR-positive)](https://onco.cc/biomarkers/sstr-pet-expression/)
- cancers: [Biochemical recurrence of prostate cancer](https://onco.cc/cancers/prostate-bcr/), [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/), [Metastatic hormone-sensitive prostate cancer](https://onco.cc/cancers/prostate-mhspc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [177Lu-PSMA-I&T](https://onco.cc/drugs/lu177-psma-it/), [Actinium-225 PSMA agents](https://onco.cc/drugs/ac225-psma/), [Flotufolastat F-18](https://onco.cc/drugs/flotufolastat/), [Gallium-68 gozetotide (PSMA-11)](https://onco.cc/drugs/ga68-psma-11/), [Illuccix (kit for Ga-68 gozetotide)](https://onco.cc/drugs/illuccix/), [Locametz (kit for Ga-68 gozetotide)](https://onco.cc/drugs/locametz/), [Lutetium-177 vipivotide tetraxetan](https://onco.cc/drugs/pluvicto/), [Piflufolastat F-18 / Pylarify TruVu](https://onco.cc/drugs/pylarify/)
- terms: [PRRT (peptide receptor radionuclide therapy)](https://onco.cc/terms/prrt-term/), [Theranostics](https://onco.cc/terms/theranostics/)
- targets: [PSMA](https://onco.cc/targets/psma/)

---
JSON: https://onco.cc/api/v1/entities/psma-pet-expression.json